Radium223—Where Does It Fit in the Metastatic Castration-Resistant Prostate Cancer Treatment Landscape?

Oncology & Hematology Review (US)
doi 10.17925/ohr.2015.11.02.135
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Touch Medical Media, Ltd.

Related search

Patient Reported Outcomes in Metastatic Castration-Resistant Prostate Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy

Klinicka Onkologie
Oncology
2016English

Pcn346 - Disease Specific Cost Analysis of the Nonmetastatic Castration-Resistant Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer Health States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Metastatic Castration-Resistant Prostate Cancer: The Emerging Continuum of Care

Journal of the Canadian Urological Association
OncologyUrology
2013English

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

Clinical Medicine Insights: Oncology
Oncology
2013English

Molecular Profiling Stratifies Diverse Phenotypes of Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Investigation
Medicine
2019English

Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Urology
Urology
2016English

The Contemporary Use of Radium-223 in Metastatic Castration Resistant Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2018English

Prostate-Specific Membrane Antigen–Directed Therapy for Metastatic Castration-Resistant Prostate Cancer

Cancer Journal
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy